Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 12-Month High – Still a Buy?

Posted by Geri Gentry on Oct 9th, 2026

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $41.69 and last traded at $41.2480, with a volume of 2502662 shares. The stock had previously closed at $39.25.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings lowered shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Oppenheimer initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 target price for the company. TD Cowen assumed coverage on Teva Pharmaceutical Industries in a research note on Thursday, October 1st. They set a “buy” rating and a $55.00 price target on the stock. Barclays upped their price target on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Finally, Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.67.

Get Our Latest Stock Analysis on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Price Performance

The stock has a market cap of $48.32 billion, a price-to-earnings ratio of 69.07, a price-to-earnings-growth ratio of 3.61 and a beta of 0.89. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The company’s 50-day moving average is $37.52 and its 200-day moving average is $34.43.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The company had revenue of $4.14 billion for the quarter. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the transaction, the insider owned 8,500 shares of the company’s stock, valued at $330,225. This represents a 46.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 374,959 shares of company stock worth $14,644,285. 0.54% of the stock is owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in the company. Cornerstone Planning Group LLC boosted its position in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after buying an additional 755 shares in the last quarter. Western Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $43,000. Sunbelt Securities Inc. bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $45,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 64.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock worth $50,000 after acquiring an additional 647 shares in the last quarter. Finally, CX Institutional acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.